Eden Research Share Discussion Threads

[supersonico] 19/12/2019 16:31

The possible/wild Guess Eden related Xinova connections uncovered thus far include PepsiCo (potato research) Eastman and Mars, but as you say Xinova relationship is yet to bear it's pipeline fruit.





Experienced Technology Manager with a demonstrated history of working in the chemicals industry and collaboration with universities. Skilled in Research and Development (R&D), management of technical programs and growth projects within the corporate technology portfolio. Experienced in developing and managing secrecy agreements, MOU's, LOI's and collaboration agreements. Strong project management professional and supervisor/mentor with a Ph.D. from UCI and a post-doc in Organic Chemistry from Oregon State University.

[attyg] 19/12/2019 12:36

Very interesting find super.
Xinova has yet to produce any new developments from the Eden IP.

Could this be one?

Interesting.

[supersonico] 19/12/2019 11:53

Food, Pets, sustainability BS and essential oils..Could this be an Eden Pipeline contender ??





The present invention relates to a composition for use as an oral antiparasitic agent, which composition comprises gamma-terpinene, and / or carvacrol, and / or thymol, and / or terpineol, and / or eucalyptol, and And / or one or more of essential oils containing eugenol, Cinnamomum, Eugenia, Eucalyptus essential oil, or a source of saponin. The invention also relates to a method for preventing or treating a parasitic infection in an animal, the method comprising gamma-terpinene and / or carvacrol and / or thymol and / or terpineol and / or eucalyptol, And / or a composition comprising one or more of eugenol-containing essential oil, Cinnamomum, Eugenia, Eucalyptus essential oil, or a source of saponin, is orally administered to the animal. Including that.

Parasite infections can affect all animals. In particular, dogs and cats are the main hosts for parasites, and at least 80% of dogs and cats are infected with certain endoparasites. In the breeding environment, 20-30% of dogs and cats are particularly susceptible to some endoparasites such as coccidium. Parasitic infections cause symptoms such as worm infestation, abdominal pain, bowel obstruction, diarrhea, and vomiting, and ultimately dehydration, insomnia, anemia, muscle or joint pain, allergies, and / or Or it can cause fatigue. In particular, cats and dogs are hosts of many parasites, and therefore close contact can lead to an increased risk of parasitic infections to humans (Zoo contagious diseases).
Plant extracts have been used in combination with chemical agents for application to the skin of animals, particularly as spot-on antiparasitic medicaments, as for example in US Pat. The problem with these spot-on methods is that the animal's skin becomes irritated and can cause skin damage.

[supersonico] 19/12/2019 07:47

Felicidades Eden.

Some observations.

Cedroz being approved faster than Dec 18 Sipcam related Mevalone approvals.



I recently commented on what I considered to be a new Country approvals strategy. This statement imo supports that assertion.

Eastman will now embark on a roll-out of Cedroz in the coming year, which includes extensive live trials under local conditions to determine the best possible use of Cedroz in different scenarios and for a range of crops. Experience has shown that an extensive and controlled trial period is essential to the success of such a product launch."



The slower Sipcam / Mevalone approvals either enhances my country approval theory or the Formulation tweak theory or they are both just wild guesses.

[supersonico] 14/12/2019 20:40

Brucie,

Lots on line from RFK jr on this subject. He was also part of the team that won the first few Bayer Glyphosate trial.



#USAutistic

[supersonico] 13/12/2019 15:27

A new report by the Centers for Disease Control and Prevention, which uses research by Rutgers University, shows a significant increase in the percentage of 4-year-old children with autism spectrum disorder in New Jersey.

The study found the rate increased 43 percent from 2010 to 2014 in the state.
The report, released April 11, found that about one in 59 children has autism. New Jersey's rate was the highest of the states studied: one in 35. That puts the national rate of autism at 1.7 percent of the childhood population and New Jersey's autism rate at 3 percent.

New Jersey is known for excellent clinical and educational services for autism spectrum disorder, so the state's higher rates are likely due to more accurate or complete reporting based on education and health care records, the researchers said. Similar studies were conducted in Arizona, Colorado, Missouri, North Carolina, Utah and Wisconsin.

[brucie5] 13/12/2019 14:21

Super, have a tick up; not from any sense except utter weariness and resignation to the unfolding consequence of last night. As you say, I hope Boris builds some more hospitals to keep us in the state to which Trump aims to get us accustomed. The wealthy, of course, will be eating organic. It's the poor who really don't matter. To either of the lying blond charlatans.

[chrischas] 13/12/2019 13:52

I see that honorable decent man has not resigned.

[supersonico] 13/12/2019 13:14

From the fella who's EPA has Bayer's back on Glyphosate and reapproved chlorpyrifos. The turkeys voted for Gut biome destruction, higher drug bills and new shiny hospitals to monetise their immune systems collapse. Bless ..what would Darwin say about Boris the new American corporate vultures wet dream?

Welcome Autism..the next marketing target.

Donald J. Trump@realDonaldTrump
·Congratulations to Boris Johnson on his great WIN! Britain and the United States will now be free to strike a massive new Trade Deal after BREXIT. This deal has the potential to be far bigger and more lucrative than any deal that could be made with the E.U. Celebrate Boris!
…………………….

[supersonico] 12/12/2019 17:12

Revised strategy by/with Partners Sipcam/Sumiagro/ Sumitomo related / Eastman

[chrischas] 12/12/2019 16:21

A revised strategy by whom?

Whatever you have in front of you ,you adapt.

Or you go under.

[supersonico] 12/12/2019 15:54

Just to be Clear Chrischas.
The parallel delays I refer to are TT/CAP formulation related and not Crop protection.
The delay in announcing country approvals imo is a revised strategy. Of course It could have a formulation component but that would be an even wilder guess than my already wild guesses.

If I was not under SANDA's I could offer you further evidence but I'm tight lipped as is Mrs100k who has no wish to see a higher share price for a while.

[supersonico] 12/12/2019 13:56

Investing,
That's not a better explanation. That's just hoping their is one.

[investingisatrickygame] 12/12/2019 12:06

I don't know what the answer is and the delays are very frustrating given Malta's approval sometime ago. What specifically is it that country x, y and z have to approve separately post Malta or do they just have a huge pile of paper which they then rubber stamp when they get to the Eastman submission? I don't understand the relevance of Malta's approval if each of the European countries cannot start trading in said products immediately thereafter. Seems stupid to me. Someone should explain that clearly to all of us.

I think it would be very wrong or Eden to contribute to delays and alignment and I'm pretty certain the LSE-AIM would have something to say about that, as would their agent, Eden's nominated adviser, Cenkos. I don't believe Eden is playing that game, but they would be foolish in my opinion if as you suggest, they are.

[supersonico] 12/12/2019 10:36

Investing,

So where are they? what's your better explanation for delays in both country approvals and formulation?

Are you not getting a little frustrated by the incongruence of what Eden say and then do?
…………..

[investingisatrickygame] 12/12/2019 10:05

Whose managing the approvals super? Eden (unlikely) or Eastman and Sipcam and why would they do so, even if they could, when that means delayed revenue, market share and profit!

[supersonico] 11/12/2019 17:18

Are we all in agreement yet?

Parallel Delays
Managed Country approvals.

[supersonico] 11/12/2019 16:14

I'm sure Mrs100K will welcome their generosity.

[northwick] 11/12/2019 15:59

Someone still wishes to offload their holding.

[supersonico] 11/12/2019 09:22

Welcome back Mrs100k

[supersonico] 11/12/2019 08:46

Dicamba drift still a big problem for Bayer.

[supersonico] 09/12/2019 15:10

French health agency ANSES announces withdrawal of 36 glyphosate products



Following the five-year re-approval of the active substance glyphosate by the European Union in 2017, the French health and safety agency ANSES is reviewing the market authorisations for glyphosate products sold in France and has launched a comparative assessment of the available alternatives.

Without waiting for the end of the current process, the Agency has notified the withdrawal of authorisations for 36 glyphosate products and the refusal to authorise 4 new products, as the data provided by manufacturers did not allow a decision to be taken on their possible genotoxicity. In 2018, these products accounted for nearly three-quarters of the tonnage of glyphosate-based products sold in France for agricultural and non-agricultural uses.

The assessment, at the level of each European Member State, of the applications for authorisation submitted by companies wishing to renew or obtain permission for marketing pesticide products, takes place within a framework defined by the European Union.

For glyphosate, this framework was specifically strengthened in 2017 following the re-evaluation of the active substance, with more requirements involving the provision of additional data on health and environmental risks, in particular on the genotoxicity of all components of glyphosate-based products. These new provisions require specific studies conducted according to standardised and robust methods.

Currently, 69 glyphosate-based products are available on the market in France and have been the subject of a request for renewal of their authorisation. As a result of ANSES's decision, 36 of these products will be withdrawn from the market and can no longer be used from the end of 2020, due to the lack of scientific data to rule out any genotoxic risk.

In addition, and for the same reasons, the Agency notified a negative decision for 4 of the 11 new applications for authorisation submitted since January 2018 that are currently under examination.

ANSES is continuing to examine applications for authorisation and re-authorisation of glyphosate products and, as announced in November 2018, will also carry out a comparative assessment of the non-chemical alternatives available.

Only glyphosate-based products that meet the efficacy and safety criteria defined at European level for the claimed uses, and that cannot be satisfactorily substituted, will ultimately benefit from access to the French market. The entire evaluation process will be completed by 31 December 2020.

[supersonico] 08/12/2019 17:29

739 of 741
Investing,
Friday saw just under £50K in buying activity. Not bad by Eden's recent standards.

[chrischas] 08/12/2019 16:24

You don’t also take too much value out of a company before it can sustain itself.
When the value is there ok you can justify it.They need to start justifying themselves.